Fairmount Funds Management LLC - 09 Jun 2025 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: VRDN
Reported as of: 09 Jun 2025
Net transaction value: +$166,355
SEC form: 4
Accepted by SEC: 11 Jun 2025, 17:00:11 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 12 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 11 Jun 2025.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 Jun 2025, 17:00.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: +$166,355.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC
Signature date: 11 Jun 2025

CIK 0001830382

Fairmount Healthcare Fund II GP LLC

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II GP LLC
Signature date: 11 Jun 2025

CIK 0001769651

Fairmount Healthcare Fund II L.P.

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II L.P
Signature date: 11 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRDN transaction

Common Stock

Options Exercise

Transaction value: $12,480
Shares: +1,600
Change %: +0.05%
Price: $7.80
Shares after: 3,447,413
Date: 09 Jun 2025
Ownership: Fairmount Healthcare Fund II LP
Footnotes: F1

VRDN transaction

Common Stock

Options Exercise

Transaction value: $153,875
Shares: +12,500
Change %: +0.36%
Price: $12.31
Shares after: 3,459,913
Date: 10 Jun 2025
Ownership: Fairmount Healthcare Fund II LP
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRDN transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -1,600
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 09 Jun 2025
Ownership: By: Peter Harwin
Underlying class: Common Stock
Underlying amount: 1,600
Exercise price: $7.80
Footnotes: F2, F3

VRDN transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -12,500
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 10 Jun 2025
Ownership: By: Peter Harwin
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $12.31
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Footnote F2

Beginning on October 27, 2020, the option vested monthly over a three-year period, subject to Peter Harwin's continued service to the Issuer. Mr. Harwin, a Managing Member of Fairmount and Fairmount GP II, served on the Issuer's Board of Directors through March 10, 2025.

Footnote F3

Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC remarks

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC.